Haruta also reported that the use of ZSTK474 as a pan-class I PI3K inhibitor could improve inflammation and disease progression in RA 36; however, the application of PI3K/AKT inhibitors on PVNS treatment have not been previously reported. Here, AKT1 is linked to rheumatoid arthritis.